Kontafarma China Holdings Ltd AI Stock Analysis
Want to see HK:1312 full AI Analyst Report?
Kontafarma China Holdings Ltd (1312) AI Stock Analysis
Kontafarma China Holdings Ltd
(HKEX:1312)
The stock earns a low overall score primarily due to severe and ongoing net losses and deeply negative profitability, partially offset by improving cash generation and reduced leverage, while technicals indicate only a modestly positive, low-volatility trend and valuation metrics provide limited evidence of clear upside.
Kontafarma China Holdings Ltd (1312) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 167.36M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.21M
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 0.31
- Revenue Growth
- -5.20%
- EPS Growth
- 41.38%
- Country
- Hong Kong
- Employees
- 625
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Kontafarma China Holdings Ltd Business Overview & Revenue Model
Company Description
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory go...
Kontafarma China Holdings Ltd Financial Statement Overview
Summary
Overall financial performance is weak, with escalating net losses and deeply negative net margins despite strong gross margins, while deleveraging and improving operating and free cash flow provide only a partial offset.
Income Statement
28NegativeBalance Sheet
62PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 845.33M | 914.71M | 897.52M | 809.11M | 894.06M | 803.27M |
| Gross Profit | 437.76M | 513.64M | 516.16M | 471.29M | 506.22M | 396.18M |
| EBITDA | 12.29M | -151.75M | 6.71M | 78.50M | 36.29M | 25.23M |
| Net Income | -212.80M | -427.85M | -75.54M | -28.84M | -41.55M | -15.05M |
Balance Sheet | ||||||
| Total Assets | 997.37M | 1.07B | 1.59B | 1.73B | 2.12B | 2.56B |
| Cash, Cash Equivalents and Short-Term Investments | 67.62M | 66.06M | 90.58M | 87.66M | 142.59M | 183.96M |
| Total Debt | 189.76M | 203.68M | 297.19M | 333.82M | 590.72M | 728.95M |
| Total Liabilities | 579.08M | 588.92M | 625.90M | 665.39M | 964.16M | 1.22B |
| Stockholders Equity | 510.20M | 553.26M | 978.70M | 1.06B | 1.10B | 1.19B |
Cash Flow | ||||||
| Free Cash Flow | 9.57M | 53.15M | 33.41M | 12.92M | -53.84M | -49.31M |
| Operating Cash Flow | 29.21M | 76.68M | 47.05M | 37.12M | -2.17M | 75.07M |
| Investing Cash Flow | 6.65M | 8.82M | -6.01M | 144.14M | 121.53M | 23.24M |
| Financing Cash Flow | -56.89M | -90.16M | -42.52M | -198.81M | -137.33M | -99.80M |
Kontafarma China Holdings Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1312, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 122.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1312.
Kontafarma China Holdings Ltd Peers Comparison
Overall Rating
HK:086870.1Outperform- HK:131251.3Neutral
HK:125250Neutral
HK:184745Neutral
HK:330045Neutral
HK:332342.8Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0868 | 70Outperform | HKD 37.67B | 11.23 | 7.71% | 4.33% | ― | ― |
| HK:1312 | 51Neutral | HKD 156.20M | -0.79 | -40.02% | ― | -5.20% | 41.38% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1252 | 50Neutral | HKD 739.99M | 2.15 | 1.79% | ― | ― | ― |
| HK:1847 | 45Neutral | HKD 44.18M | -0.71 | -18.70% | ― | 43.00% | -74.41% |
| HK:3300 | 45Neutral | HKD 496.84M | -0.09 | 98.32% | ― | ― | ― |
| HK:3323 | 43Neutral | HKD 21.49B | -2.12 | -5.48% | 6.25% | 0.12% | -214.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1312 | Kontafarma China Holdings Ltd | 0.03 | 0.00 | 11.11% | |
| HK:3323 | China National Building Material Co Class H | 2.74 | -2.74 | -49.98% | |
| HK:0868 | Xinyi Glass Holdings | 8.42 | -0.54 | -6.07% | |
| HK:3300 | China Glass Holdings Limited | 0.28 | -0.38 | -57.58% | |
| HK:1252 | China Tianrui Group Cement Co., Ltd. | 0.24 | -0.09 | -26.15% | |
| HK:1847 | YCIH Green High-Performance Concrete Co., Ltd. Class H | 0.33 | -0.31 | -48.44% |
Kontafarma China Holdings Ltd Corporate Events
Kontafarma China Wins Second Waiver on Delayed Lease Circular
Kontafarma China Holdings Limited has received a second waiver from the Hong Kong Stock Exchange allowing a further extension to dispatch a shareholder circular related to the renewal of a lease for its fitness and yoga centre. The circular, which wi...
Kontafarma Moves to Liquidate Loss-Making Singapore Fitness Subsidiaries
Kontafarma China Holdings Ltd has disclosed that its indirect Singapore subsidiaries True Fitness Pte. Ltd. and True Yoga Pte. Ltd. have passed resolutions to initiate creditors’ voluntary winding-up under Singapore’s Insolvency, Restructuring and Di...
Kontafarma China Seeks Second Waiver as Lease Circular Faces Further Delay
Kontafarma China Holdings, a Cayman Islands-incorporated company listed in Hong Kong, operates fitness and yoga centres and manages significant lease arrangements tied to these facilities. The group is overseen by a board led by Chairman Wang Limin,...
Kontafarma China Narrows Interim Loss Despite Revenue Decline
Kontafarma China Holdings reported unaudited interim results for the six months ended June 30, 2026, showing revenue of HK$383.3 million, down from HK$452.7 million a year earlier. The group’s gross profit fell to HK$178.7 million, and it recorded a...
Kontafarma Reshapes Top Management With New President and Executive Director
Kontafarma China Holdings Ltd has announced an internal reshuffle in its senior management, with chairman and executive director Wang Limin stepping down as president of the group while retaining his board roles and chairmanship of key governance com...
Kontafarma China Refines Board and Committee Structure for Stronger Governance
Kontafarma China Holdings Ltd has updated its board composition effective 17 August 2026, confirming a seven-member Board comprising four executive directors and three independent non-executive directors. Wang Limin serves as chairman, supported by k...
Kontafarma China Delays Circular on Major Fitness Centre Lease Renewal
Kontafarma China Holdings Limited has postponed the despatch of a shareholder circular relating to the renewal of a lease for an existing fitness and yoga centre, classified as a major transaction under Hong Kong listing rules. The circular, original...
Kontafarma China Sets August Board Meeting to Review Interim Results and Dividend
Kontafarma China Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, is guided by a seven-member board featuring four executive directors and three independent non-executive directors. The team is led by Chairman Wang Limin...
Kontafarma Flags Smaller First-Half Loss Amid Fresh Singapore Fitness Impairments
Kontafarma China Holdings has warned that it expects to post a consolidated net loss of between HK$67.2 million and HK$100.7 million for the six months ended 30 June 2026, a substantial improvement from the HK$321.4 million loss a year earlier. The n...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026